CDKN2A and glioma: Of further relevance to the dLGG IDH-mut gliomas is the homozygous deletion of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) that is associated with markedly shorter overall survival in IDH-mut tumors (13–18).